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Abstract: Rubella-containing vaccines (RCV) are not yet part of the 
Democratic Republic of the Congo's (DRC) vaccination program; however RCV 
introduction is planned before 2020.  Because documentation of DRC's 
historical burden of rubella virus infection and congenital rubella 
syndrome (CRS) has been minimal, estimates of the burden of rubella virus 
infection and of CRS would help inform the country's strategy for RCV 
introduction. 
 
A rubella antibody seroprevalence assessment was conducted using serum 
collected during 2008-2009 from 1,605 pregnant women aged 15-46 years 
attending 7 antenatal care sites in 3 of DRC's provinces.  Estimates of 
age- and site-specific rubella antibody seroprevalence, population, and 
fertility rates were used in catalytic models to estimate the incidence 
of CRS per 100,000 live births and the number of CRS cases born in 2013 
in DRC. 
 
Overall 84% (95% CI 82, 86) of the women tested were estimated to be 
rubella antibody seropositive.  The association between age and estimated 
antibody seroprevalence, adjusting for study site, was not significant 
(p=0.10).  Differences in overall estimated seroprevalence by study site 
were observed indicating variation by geographical area (p<=0.03 for 
all).  Estimated seroprevalence was similar for women declaring residence 
in urban (84%) versus rural (83%) settings (p=0.67).  In 2013 for DRC 
nationally, the estimated incidence of CRS was 69/100,000 live births 
(95% CI 0, 186), corresponding to 2886 infants (95% CI 342, 6395) born 
with CRS.    
 
In the 3 provinces, rubella virus transmission is endemic, and most viral 
exposure and seroconversion occurs before age 15 years.  However, 
approximately 10%-20% of the women were susceptible to rubella virus 
infection and thus at risk for having an infant with CRS.  Per World 
Health Organization recommendations, introduction of RCV should be 
accompanied by a campaign targeting children 9 months to 14 years and 
vaccination of women of child bearing age through routine services.   
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Global Immunization Division, 
Center for Global Health,  
Mailstop A-04,  
Atlanta, GA 30333 
21 October 2016 
 
The Editor  
Vaccine 
 
 
Dear Sir or Madam: 
 
On behalf of my co-authors, we thank Vaccine for the reviewers’ comments received regarding the manuscript, 
“Estimating the Burden of Rubella Virus Infection and Congenital Rubella Syndrome through a Rubella Immunity 
Assessment among Pregnant Women in the Democratic Republic of Congo: Potential Impact on Vaccination 
Policy”.  We would also like to thank Vaccine for providing us with 2 additional weeks to prepare our revisions. 
 
Please find below our responses (in italics in blue below each reviewer’s comments) to the comments and the 
details describing how the manuscript was revised to address each.   
 
Reviewer #1: This manuscript provides estimates of Congenital Rubella Syndrome (CRS) for the Democratic 
Republic of Congo (DRC) using seroprevalence data obtained from existing blood specimens from antenatal 
clinics. It provides an idea of the occurrence of CRS in a country with little rubella data and that has not yet 
introduced a rubella-containing vaccine, thus shedding light on an issue that is relevant when discussing vaccine 
introduction and vaccination strategies. The paper is well written and the supplemental material useful to 
understand the models used.  
 
Specific comments: 
 
Abstract 
 
1. What % of the population live in the selected provinces  
 
Additional details regarding a number of elements of DRC’s population have been incorporated into the Methods 
section of the manuscript (Please see lines 193-199, lines 206-211, and lines 252-257).   
 
2. Clarify that the estimated CRS incidence and cases in 2013 is for all of DRC 
 
The abstract has been revised to read “In 2013 for DRC nationally, the estimated incidence of CRS was 
69/100,000 live births (95% CI 0, 186), corresponding to 2886 infants (95% CI 342, 6395) born with CRS.”    
 
Introduction 
 
1. Consider changing deafness for hearing impairment  
 
Lines 88-89 have been revised to replace the word “deafness” with “hearing impairment”.  The sentence now 
reads “CRS can result in hearing impairment, blindness, congenital heart disease, mental retardation, and/or 
other manifestations [1-2].” 
*Response to Reviewers
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2. Are the tentative plans for RCV intro in the country multiyear plan? Is this in any document from Gavi, the 
Vaccine Alliance? What is the source of this assertion? 
 
The comprehensive Multi-Year Plan (cMYP) 2015-2019 prepared by DRC’s Ministry of Public Health in November 
2014 has, as one of its objectives, the introduction of rubella-containing vaccine via routine vaccination services.  
This document has been added to the reference list (Reference 10) and is now referenced in the text at the 
appropriate places.   
 
Methods 
 
1. How were the 7 sites in the 3 provinces selected? 
 
The rubella serosurvey described in the manuscript was conducted using serum available after the conduct of a 
polio serosurvey in adults in the 7 ANC sites in the 3 provinces [Reference 15].  We hope that lines 128-133 more 
clearly explain this; a reference to a publication describing the polio serosurvey has been added [Reference 15].  
The wording now states “Sera prepared from venous blood collected during 2008-2009, per WHO guidelines from 
6,615 pregnant women aged 15-47 years from 7 ANC sites in Bandundu, Kinshasa, and Kasaï Occidental 
provinces for national HIV sentinel serosurveys in DRC, had been used for a polio serosurvey in adults and were 
available for additional testing [13-16].” 
 
Details for how the national HIV sentinel ANC serosurvey selected the sites are described in lines 123 –125 in the 
Methods section [Reference 16]. 
 
2. What % of DRC's population live in those provinces? This could be even presented in the map. 
 
See comments above. 
 
3. Why were the equivocals classified as seronegative? This is exactly the opposite from what the same authors 
did for the PLoS 2016 paper by Vynnycky et al. It is a small number of samples, but it is curious.  
 
The reviewer notes that “it is a small number of samples, but it is curious”.  Yes, that is correct.  Only 14 of the 
women fell into the equivocal category.  The 14 were distributed among 3 study sites among women whose ages 
are listed in parentheses after the study site name in the list that follows:  Mikalayi (n=6, ages =17, 19, 22, 23, 37, 
38), Vanga (n=1, age =34), Tshikapa (n=4, ages =17, 29, 34, 35) and Kinshasa (n=3, ages =17, 17, 18).  These 
details have been added to the Methods section in lines 167-169. 
 
The reviewer is correct about the classification of the equivocals in the 2016 PLoS article by Vynnycky et al.  To 
address this we have conducted the analyses in both ways and have added the results with the equivocals 
classified as seropositive to the article supplement.  Please see lines 251-257, 327-329 and the supplement Table 
S3. 
 
4. Clarify in this section how the DRC country estimate for CRS is obtained. It is more apparent after seeing table 
2 and the supplemental material, but it would be better if it were better explained in the main Methods section. 
 
We are pleased that the reviewer found the supplemental materials of use in understanding the methodology 
behind the DRC country estimate for CRS.  We hesitate to add more explanation of the methods to the main 
manuscript as we are already above Vaccine’s word limit.  In addition, we think that it would make the text very 
heavy.  If the Editor feels differently, we proposing adding the entire supplement text to the main manuscript to 
provide the requested detail.   
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5. Table 2. Please confirm the 95% CI for estimated number of CRS cases in Kinshasa.  
 
In reviewing our analyses for this manuscript revision, we realized that we needed to account for the differing 
population estimates for DRC that are found in United Nations documents versus those available from the 
Expanded Programme On Immunization-Ministry of Public Health.  Moreover, we were able to find a source for 
the age distribution of the female population in urban and rural areas in the 2013/2014 DHS [Reference 17].  
Please see lines 190-217 of the Methods section for a complete description.  As a consequence, we have new 
estimates for the numbers of CRS cases born in DRC in 2013 in the various sites and settings, based on the two 
differing population sources.  Please see Tables 2 and S3 for the detailed results. 
 
Discussion 
Are the authors proposing that a rubella vaccination policy should include catch-up of WCBA? Given the lack of 
differences seen in seroprevalence, this has important implications and could be better tackled. 
 
These authors are not proposing catch-up campaigns for WCBA.  The authors state that WCBA should be 
considered for rubella vaccination through routine services.  Please see the Conclusion section of the abstract and 
lines 372-373 of the discussion.   
 
In line 350, the authors indicate that DRC would have to establish nationwide CRS surveillance. Is this always so? 
Where is it recommended? Would CRS in sentinel sites plus "good" rubella surveillance be adequate to monitor 
CRS? 
 
The sentence in lines 380-384 has been revised and hopefully will address the concern of Reviewers 1 and 4.  The 
sentence now reads “Therefore, during the years before introducing RCV, DRC will need to a) focus efforts on 
improving the delivery of measles vaccination, thereby creating a successful platform on which to introduce 
rubella vaccination; b) establish an integrated nationwide measles-rubella surveillance system as well as, at 
least, sentinel sites for CRS surveillance; and c) use best practices from measles vaccination campaigns to assure 
a high-quality rubella wide-age campaign.” 
 
The 2013-2014 DHS cited here (ref 15) collected blood and did serology for measles among other pathogens, 
would that be a possibility to explore in the future to monitor rubella seroprevalence? 
 
We appreciate the reviewer’s comments regarding the serological studies conducted in DRC as part of the 2013-
2014 DHS.  We agree that such studies are a possibility for monitoring rubella seroprevalence.  Unfortunately, 
the results of those serological studies conducted as part of the 2013-2014 DHS have not yet been published; 
thus, we could not include them as part of our discussion.  
 
References 
Ref 18. The 2015 revision is already available. Not to change anything, but just for information.  
 
The authors thank the reviewer for this information. 
 
Reviewer #3: This paper adds important information regarding the epidemiology of rubella in Africa, specifically 
in one of its largest countries, DRC.  The information allows for better vaccination strategies.  The strength of the 
paper is the large number of women tested for rubella antibodies, revealing substantial susceptibility to rubella, 
similar to the US before introduction of vaccination.  It also shows that rubella circulation is mainly in children 
less than 15 years, who therefore must be the source of infection during pregnancy.  The estimate made of 
congenital rubella cases suggests that CRS is an important public health problem in DRC.  However, the paper 
has several weaknesses that should be addressed: the use of the ELISA test, which usually underestimates 
4 
 
protection, and in particular the estimate of CRS incidence, which is based on calculations of force of infection, 
not surveillance.  The very wide confidence limits testify to the limitations of the estimate. 
 
The reviewer is correct that a small percentage of individuals who are immune to rubella do not have ELISA titers 
indicating an IU/ml level above 10.  However, in a population not selected for low IgG titers, this is a very small 
percentage of individuals who have been vaccinated or have had wild type rubella.  For example, in a vaccination 
study in toddlers in Bangladesh, less than 0.5% did not respond with =>10 IU/ml after a single dose of RCV*.  On 
the other hand, in a population selected for a low response, immunity determinations can be difficult$. 
 
For the population in question here, the small percentage of immune persons who do not have 10 IU/ml should 
not affect the results.  A sentence has been added to the Methods section to reflect this; please see lines 169-170. 
 
*J Infect Dis. 2016 Jun 1;213(11):1686-93. doi: 10.1093/infdis/jiw024. Epub 2016 Jan 27.  Noninterference of 
Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus 
Immunity: A Randomized Trial. 
 
$J Clin Microbiol. 2016 Jul;54(7):1720-5. doi: 10.1128/JCM.00383-16. Epub 2016 May 4.  Assessing Immunity to 
Rubella Virus: a Plea for Standardization of IgG (Immuno)assays. 
 
Since there is currently no surveillance for CRS in DRC, CRS surveillance data cannot be used to estimate CRS 
incidence in DRC at this time.  This is unfortunate.  However, rubella antibody seroprevalence data were available 
and were paired with an established mathematical modeling methodology, which has been used to estimate the 
global burden of Congenital Rubella Syndrome.  These authors acknowledge in Discussion lines 413-418 the wide 
confidence intervals, often approaching zero, associated with the CRS incidence and case number estimates.  
Similarly wide confidence intervals, with the lower limit approaching zero, have been found for estimates of the 
CRS incidence and burden for other countries [Reference 24].  However, we note that while the lower 95% 
confidence limit approaches zero for the numbers of cases of CRS in different parts of DRC, it does not approach 
zero for the national estimate of the burden of CRS.  Our work therefore suggests that there is potentially a non-
negligible burden of CRS, which should be investigated in further studies.  The study is also the largest study of 
rubella seroprevalence in DRC to date and therefore provides a reference point for researchers wishing to 
estimate the burden of CRS in DRC in the future.  
 
Reviewer #4: Congratulations to the authors for preparing a well written summary of an investigation using 
existing blood serum collected in 2008-2009 to test for HIV from women attending antenatal care clinics in the 
Democratic Republic of Congo.  A sample of the stored sera was selected from seven clinics (three from 
Kinshasa) to estimate the percent of pregnant women with rubella-specific antibodies.  The article contributes 
to knowledge about rubella immunity prior to introduction of rubella containing vaccine in a national 
immunization program. 
 
I have the following specific comments: 
 
1. Abstract results, lines 68-70:  I'm not sure that I understand the rationale for showing a statistically significant 
result between one province when compared to four of five of the other sites.  Why not include all sites?  
Alternatively, maybe it would be better to describe the differences of urban vs. rural, or Kinshasa vs other sites. 
 
The results section of the abstract has been revised; please see the text in the following paragraph.  The results 
regarding the differences in the various geographical areas are now presented in more general terms, and the 
results for rural versus urban settings have been added. 
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“Overall 84% (95% CI 82, 86) of the women tested were estimated to be rubella antibody seropositive.  The 
association between age and estimated antibody seroprevalence, adjusting for study site, was not significant 
(p=0.10).  Differences in overall estimated seroprevalence by study site were observed indicating variation by 
geographical area (p<=0.03 for all).  Estimated seroprevalence was similar for women declaring residence in 
urban (84%) versus rural (83%) settings (p=0.67).  In 2013 for DRC nationally, the estimated incidence of CRS was 
69/100,000 live births (95% CI 0, 186), corresponding to 2886 infants (95% CI 342, 6395) born with CRS”. 
 
2.  Abstract conclusions, lines 77-78:  The recommendation to target women of child bearing age is not well 
described.  I would suggest the recommendation be to conduct a wide age range campaign targeting all children 
9 months to 14 years as well as vaccinating women of child bearing age through routine immunization services 
as described in lines 338-341. 
 
The concluding statement of the abstract has been revised as suggested by the reviewer.  The concluding 
statement now reads as follows:  “Per World Health Organization recommendations, introduction of RCV should 
be accompanied by a campaign targeting all children 9 months to 14 years of age as well as vaccination of 
women of child bearing age through routine services.” 
 
3.  Line 111:  In my experience, ANC is usually used as the abbreviation for antenatal care rather than antenatal 
clinics. 
 
Yes, the reviewer is correct.  We appreciate the reviewer bringing this to our attention.  The wording has been 
revised throughout the manuscript. 
 
4.  Line 186-187:  Is there any estimates for the age distribution of women in rural areas vs urban areas?  If not, 
then there is no other choice but to use national estimates, but it seems that rural vs urban may have very 
different distributions depending on migration patterns. 
 
We appreciate this question which prompted us to look again for such data.  We found that the 2013/2014 DRC 
Demographic and Health Survey [Reference 17] had an estimate of the age distribution of women in rural versus 
urban areas.  The analyses were rerun using the respective age distributions, and the revised results are 
presented in Table 2 in the main manuscript and in Table S3 of the supplement.   
 
5.  Line 194:  This sentence states "the remaining were considered rural".  Since the remaining are only two 
sites, wouldn't it be more clear to state "the remaining two sites" or better yet list the names of the sites 
considered rural? 
 
The sentence in lines 204-205 has been revised according to the reviewer’s suggestion.  It now reads “In these 
analyses, the Kinshasa, Kikwit and Tshikapa study sites were considered urban, and the Mikalayi and Vanga sites 
were considered rural [13, 14, 17].”   
 
6.  Lines 249-250:  I would suggest to include the percentages of women in each of the population groups 
described. 
 
The authors appreciate the reviewer’s suggestion.  We would prefer to leave those details out of the body of the 
text since their inclusion could render the text heavy and hard to read.  All details are available in Table 1, and 
readers are guided to Table 1 in lines 274-275. 
 
7.  Lines 269-271:  The sentence may imply that the results of statistical tests were displayed in Table 1.  I would 
suggest to re-phrase as ". . . and the demographic variable categories described in Table 1 were observed." 
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The sentence in lines 295-297 has been revised according to the reviewer’s suggestion.  The sentence now reads 
“Moreover, no statistically significant associations between estimated rubella antibody seroprevalence and the 
demographic variable categories described in Table 1 were observed.” 
 
8.  Lines 350-351:  The surveillance recommendation to DRC seems too ambitious before 2020.  I would suggest 
to re-phrase as "b) establish an integrated nationwide measles-rubella surveillance system as well as at least 
sentinel sites for CRS surveillance;" 
 
The sentence in lines 380-384 has been revised according to the reviewer’s suggestion.  The sentence now reads 
“Therefore, during the years before introducing RCV, DRC will need to a) focus efforts on improving the delivery 
of measles vaccination, thereby creating a successful platform on which to introduce rubella vaccination; b) 
establish an integrated nationwide measles-rubella surveillance system as well as, at least, sentinel sites for CRS 
surveillance; and c) use best practices from measles vaccination campaigns to assure a high-quality rubella wide-
age campaign.” 
   
9.  Line 361:  could "poorly fitted" be re-phrased as "was a poor fit for" the Kinshasa rubella antibody data? 
 
The sentence in Lines 393-394 has been revised to read as follows: “We note that the selected catalytic model 
used to estimate the force of infection was a poor fit to the Kinshasa rubella antibody seroprevalence data.” 
 
Thank you for considering a revised version of the manuscript that is being submitted with this letter.  Please 
feel free to contact me if you have any questions.  
 
 
Sincerely, 
Mary Alleman, PhD, MPH 
Epidemiologist 
Global Immunization Division 
Centers for Disease Control and Prevention 
1600 Clifton Road, NE; MS-A-04 
Atlanta, GA  30333 
Tel:  (404) 431 2084   
mea4@cdc.gov 
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ABSTRACT  54 
Background:  Rubella-containing vaccines (RCV) are not yet part of the Democratic Republic of the Congo’s 55 
(DRC) vaccination program; however RCV introduction is planned before 2020.  Because documentation of DRC’s 56 
historical burden of rubella virus infection and congenital rubella syndrome (CRS) has been minimal, estimates 57 
of the burden of rubella virus infection and of CRS would help inform the country’s strategy for RCV 58 
introduction. 59 
 60 
Methods:  A rubella antibody seroprevalence assessment was conducted using serum collected during 2008-61 
2009 from 1,605 pregnant women aged 15-46 years attending 7 antenatal care sites in 3 of DRC’s provinces.  62 
Estimates of age- and site-specific rubella antibody seroprevalence, population, and fertility rates were used in 63 
catalytic models to estimate the incidence of CRS per 100,000 live births and the number of CRS cases born in 64 
2013 in DRC. 65 
 66 
Results:  Overall 84% (95% CI 82, 86) of the women tested were estimated to be rubella antibody seropositive.  67 
The association between age and estimated antibody seroprevalence, adjusting for study site, was not 68 
significant (p=0.10).  Differences in overall estimated seroprevalence by study site were observed indicating 69 
variation by geographical area (p<=0.03 for all).  Estimated seroprevalence was similar for women declaring 70 
residence in urban (84%) versus rural (83%) settings (p=0.67).  In 2013 for DRC nationally, the estimated 71 
incidence of CRS was 69/100,000 live births (95% CI 0, 186), corresponding to 2886 infants (95% CI 342, 6395) 72 
born with CRS.    73 
 74 
Conclusions:  In the 3 provinces, rubella virus transmission is endemic, and most viral exposure and 75 
seroconversion occurs before age 15 years.  However, approximately 10%-20% of the women were susceptible 76 
to rubella virus infection and thus at risk for having an infant with CRS.  This analysis can guide plans for 77 
introduction of RCV in DRC.  Per World Health Organization recommendations, introduction of RCV should be 78 
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accompanied by a campaign targeting all children 9 months to 14 years of age as well as vaccination of women 79 
of child bearing age through routine services.   80 
  81 
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 82 
INTRODUCTION 83 
Rubella is a vaccine-preventable disease with safe and effective vaccines available since 1969.  In the absence of 84 
vaccination, infection with the rubella virus usually occurs in childhood and causes a mild, self-limited illness 85 
characterized by rash and fever.  However, if rubella virus infection occurs in a susceptible woman during the 86 
first trimester of pregnancy, miscarriage, fetal death, or congenital rubella syndrome (CRS) in the surviving infant 87 
often occurs.  CRS can result in hearing impairment, blindness, congenital heart disease, mental retardation, 88 
and/or other manifestations [1-2]. 89 
 90 
A single dose of the most common rubella vaccine, RA27/3, is highly efficacious in providing lifelong protection 91 
against disease.  Prevention of congenital rubella virus infection, including CRS, is the primary goal of rubella 92 
vaccination.  The preferred approach for prevention of rubella and CRS is for countries to introduce a rubella-93 
containing vaccine (RCV) through a wide-age range campaign and then incorporate it into the national childhood 94 
vaccination schedule [2]. 95 
 96 
In recent years, several World Health Organization (WHO) regions have established rubella/CRS elimination or 97 
accelerated control goals [2-6].  In 2003 the WHO region of the Americas set a rubella/CRS elimination goal, 98 
achieved the goal in 2009, and in April 2015, was declared free of endemic rubella and CRS [2-5, 7].  The WHO 99 
European region set a 2015 rubella elimination goal [3, 4, 8].  In October 2014, a regional rubella elimination 100 
goal for the WHO Western Pacific Region was endorsed by its Regional Committee [6].  The WHO African region 101 
has not yet established a rubella elimination goal but recommends that countries document the burden of 102 
rubella virus infection/CRS and, when feasible, introduce RCVs [9]. 103 
 104 
RCVs have not been widely administered in the Democratic Republic of the Congo (DRC) nor introduced into the 105 
country’s national vaccination program [10].  However, there are tentative plans for introduction into the 106 
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childhood vaccination schedule before 2020 [10].  Documentation of DRC’s historical burden of rubella virus 107 
infection and CRS has been minimal [1, 11, 12].  Moreover, DRC has no surveillance system for either disease, 108 
but rubella virus transmission within the country has been documented by a rubella antibody seroprevalence 109 
assessment conducted in Kinshasa city in 1987-1988 and by measles case-based surveillance since 2005, with 110 
serological testing for rubella-specific immunoglobulin type M (IgM) when suspected measles cases are negative 111 
for measles IgM [1, 11, 12].  Considering the interest in rubella control/elimination in the WHO African region, 112 
estimates of the burden of rubella virus infection/CRS in DRC are urgently needed [8, 9].  We describe analyses 113 
of sera from 1,605 pregnant women aged 15-46 years from 3 provinces in DRC which were available from a 114 
human immunodeficiency virus (HIV) sentinel survey among women attending antenatal care (ANC) sites [13-115 
15].  Estimates of age- and site-specific rubella antibody seroprevalence, population, and fertility rates were 116 
used in catalytic models to estimate the incidence of CRS per 100,000 live births and the number of CRS cases 117 
born in 2013 in DRC.  These estimates will be valuable to DRC’s Ministry of Public Health (MOPH) in planning for 118 
RCV introduction [10].   119 
  120 
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METHODS 121 
Rubella antibody seroprevalence assessment 122 
HIV sentinel surveys among pregnant women attending ANC sites are based on a convenience sample of 123 
sentinel sites chosen to capture women from a variety of geographical and socioeconomic backgrounds.  Details 124 
on how sites are selected can be found here [16].  The 2008-2009 HIV sentinel surveys in DRC included 30 125 
sentinel ANC sites [13, 14].  This study focuses on a subset of 7 ANC sites in 3 provinces. 126 
 127 
Sera prepared from venous blood collected during 2008-2009, per WHO guidelines from 6,615 pregnant women 128 
aged 15-47 years from 7 ANC sites in Bandundu, Kinshasa, and Kasaï Occidental provinces for national HIV 129 
sentinel serosurveys in DRC, had been used for a polio serosurvey in adults and were available for additional 130 
testing [13-16].  Specifically, the 7 ANC sites were 1) Kikwit (urban) and 2) Vanga (rural) in Bandundu, 3) Binza-131 
Meteo, 4) Boyambi, and 5) Kingasani (all urban) in Kinshasa, and 6) Mikalayi (rural) and 7) Tshikapa (urban) in 132 
Kasaï Occidental (Figure 1).  The Demographic and Health Survey II (DHS II) conducted in 2013-2014 in DRC 133 
reported that, nationally, 88% of women aged 15-49 years participating in the survey who had a live birth in the 134 
5 years preceding the survey had sought antenatal care during their pregnancy for their most recent live birth; 135 
the results were 90%, 89%, and 96% for women declaring residence in Bandundu, Kasai Occidental, and Kinshasa 136 
provinces, respectively, and were 94% and 86% for those declaring residence in urban and rural areas, 137 
respectively [17].  A survey conducted in 2009 in Kinshasa province among women at least 18 years of age who 138 
had been pregnant within the prior 3 years reported that 98% of women surveyed had attended ANC during 139 
their most recent pregnancy [18].   140 
 141 
Sera from a randomly-sampled subset of the above-mentioned 6,615 women were quantitatively analyzed for 142 
rubella-specific immunoglobulin type G (IgG).  Prior to random sampling of the women for the rubella antibody 143 
serosurvey described in this report, HIV-positive women were excluded since HIV infection may negatively 144 
impact serum IgG levels; HIV prevalence in the 7 above-mentioned ANC sites ranged from 1.8% - 5.1% in 2008 - 145 
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2009 [13, 14, 19].  Also prior to random sampling for the rubella serosurvey, women attending the 3 ANC sites in 146 
the densely populated urban area of Kinshasa city (Binza-Meteo, Boyambi, and Kingasani) were pooled.  147 
Kinshasa was thereafter considered a single study site (referred to as the “Kinshasa” study site); thus, there were 148 
5 study sites for the serosurvey (Table 1).  From 5,829 HIV-negative women from the original 6,615, 1,650 149 
women (66 serum samples from each of 25 strata, i.e., 5 age groups from each of the 5 study sites) were 150 
randomly chosen.  The sample size was determined based on the estimation of rubella antibody seroprevalence 151 
with a precision of +/-10% assuming true prevalence of >=80% and 5% unusable serum samples.  Of the 1,650 152 
sera, 45 (3%) had insufficient volume for IgG assessment: 16, 7, 8, 10, and 4 from the Kikwit, Kinshasa, Mikalayi, 153 
Tshikapa, and Vanga study sites, respectively.  Demographic attributes (e.g., age at blood collection, age at first 154 
pregnancy, number of pregnancies, rural or urban residence, level of education, occupation, and civil status) 155 
were analyzed for associations with rubella antibody seropositivity [13, 14]. 156 
 157 
Sera were shipped by air from DRC to the Centers for Disease Control and Prevention (CDC-Atlanta) on dry ice 158 
and stored at -20oC prior to rubella IgG assessments performed at CDC-Atlanta’s Measles, Mumps, Rubella, and 159 
Herpesvirus Branch laboratory.  Rubella-specific IgG antibody concentrations, expressed as International 160 
Units/millimeter (IU/ml), were determined using the Rubella IgG ELISA II system according to the manufacturer’s 161 
instructions (Wampole Laboratories, Princeton, New Jersey).  The optical density (OD) ratio was calculated by 162 
dividing the specimen OD by the cutoff value supplied by the manufacturer.  Specimens with OD ratios >2.2 163 
were diluted with kit dilution buffer, and rubella-specific IgG antibody concentrations were determined from the 164 
diluted serum.  Sera with titers of >=10 IU/ml were considered seropositive for rubella antibody, whereas those 165 
with an equivocal determination (8.19 to 9.99 IU/ml) or with titers of <8.19 IU/ml were considered seronegative 166 
[2].  The 14 women with equivocal determination were distributed among 4 study sites as follows:  Mikalayi 167 
(n=6, ages in years=17, 19, 22, 23, 37, 38), Vanga (n=1, age in years =34), Tshikapa (n=4, ages in years=17, 29, 34, 168 
35), and Kinshasa (n=3, ages in years=17, 17, 18).  Immune individuals with ELISA-determined IgG <10 IU/ml 169 
should be too small in number to affect the results presented in this report [20].   170 
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 171 
Site-specific rubella antibody seroprevalence was estimated overall and for each 5-year age group, accounting 172 
for the sampling probability in each stratum and treating the equivocals as seronegative.  The rubella antibody 173 
seroprevalence estimates and associated confidence intervals (CIs) are representative of the study site 174 
assessment populations only and not of any DRC populations at large.  The Pearson Chi-square test was used to 175 
assess differences in rubella antibody seroprevalence overall for the 5 study sites, across 5 age strata (overall 176 
and within each site), and across the other demographic attributes (Table 1); when statistically significant 177 
differences were observed, pairwise analyses were conducted using the Pearson Chi-square test.  The Cochran-178 
Mantel-Haenszel (CMH) Chi-square was used to test for statistically significant associations between rubella 179 
antibody seroprevalence and site controlling for age and between rubella antibody seroprevalence and age 180 
controlling for site.  Tests were considered statistically significant at p<0.05. 181 
 182 
Estimating CRS incidence and the number of CRS cases born in 2013 183 
The age- and site-specific rubella antibody seroprevalence estimates were used in catalytic models to estimate 184 
the rate at which susceptible women were infected with rubella virus (i.e., force of rubella virus infection).  The 185 
force of infection estimates were then used with estimated populations and fertility rates to obtain the CRS 186 
incidence/100,000 live births in 2013 and numbers of CRS cases born in 2013.  Details follow.   187 
 188 
Demographic data  189 
The total number of women of child-bearing age (WCBA) for 2013 in the zones de santé (health zones) in which 190 
the ANC sites were situated were extracted from DRC’s Expanded Programme on Immunization (EPI)-MOPH 191 
population projections based on the 1984 census (the only official census ever conducted at the zone de santé 192 
level); health zones in DRC are the equivalent of districts in other countries [17].  Based upon those EPI-MOPH 193 
projections, in 2013 DRC’s estimated total population was 86,508,633, and the estimated total population of 194 
Bandundu, Kinshasa, and Kasaï Occidental provinces was 8,350,279, 8,103,633, and 8,252,695, respectively; 195 
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estimates indicate that in 2013 the population of WCBA in each province was 21% of the province’s estimated 196 
total population.  The 2013 estimated population of WCBA for the health zones in which the 7 ANC sites were 197 
located were as follows:  Boyambi (32,523), Binza Meteo (85,987), Kikwit (42,713), KIngasani (47,452), Mikalayi 198 
(44,715), Tshikapa (73,249), and Vanga (57,273). 199 
 200 
The age distribution of women in urban and rural areas was extracted from the 2013-2014 DRC Demographic 201 
and Health Survey [17].  To calculate site-specific numbers of women in a given age group, the total number of 202 
WCBA in the corresponding health zone was multiplied by the proportion of WCBA in the age of interest 203 
according to whether or not the site was considered urban or rural.  In these analyses, the Kinshasa, Kikwit and 204 
Tshikapa study sites were considered urban, and the Mikalayi and Vanga sites were considered rural [13, 14, 17].  205 
The total female population size (33,976,774 for 2013) and the proportion of DRC’s population living in urban 206 
and rural settings (35.4% and 64.6% respectively for 2013) were extracted from United Nations (UN) population 207 
sources, and the two were multiplied together to obtain the number of females living in urban and rural areas in 208 
DRC [20, 21].  These numbers were then scaled up by 28%, to account for a 28% difference between the 209 
population size according to UN sources and that in the DRC EPI-MOPH projections for 2013 (67,513,677 vs 210 
86,508,633, respectively).  The number of women in each five year age group (15-19, 20-24, 25-29, 30-34, 35-39, 211 
and 40-44 years) in urban and rural areas was calculated by multiplying the female population size in urban or 212 
rural areas by the proportion of the female population in the given area that was in the age group of interest 213 
[21].  Age-specific fertility rates for 2013-2014 for urban and rural settings were extracted from the 2013-2014 214 
DRC Demographic and Health Survey [17].  The number of live births in each site or setting in DRC among 215 
mothers in each 5-year age group was calculated by multiplying the corresponding age-specific fertility rates and 216 
numbers of women in the site or area of interest.   217 
 218 
CRS incidence and CRS case estimations by site 219 
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Following previous methods, four age-structured catalytic models were fitted to the observed age-stratified 220 
rubella antibody seroprevalence estimates from the different study sites using maximum likelihood to estimate 221 
the force of rubella virus infection [23-25].  This was assumed to differ (models A and B) or be identical (models 222 
C and D) for the ages <15 and ≥15 years [23, 26].  The sensitivity of the rubella serological (antibody) assay was 223 
either estimated (models A and C) or assumed to be 100% (models B and D) [23, 26].  Models A-D are described 224 
in the article supplement (Table S1).  The following equation gives the proportion of individuals of age a (s(a)) 225 
that are seronegative, where p is the sensitivity of the serological assay, and 
yλ  and oλ  are the average force 226 
of infection among younger and older individuals respectively.  227 
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Subsequent estimates of the CRS incidence were based on models that were selected according to biological 229 
plausibility using criteria described elsewhere, with the additional criterion that model B was selected in 230 
preference to model A if all the other criteria were satisfied and the estimated sensitivity of the assay was 100% 231 
for model A, and the lower limit of the 95% confidence interval was implausibly low (less than 95%) [24].  If no 232 
model provided biologically-plausible estimates or if the model fitted the data from a given site poorly (passed 233 
through the confidence intervals of one or fewer datapoints), we excluded those data from estimates for urban 234 
or rural areas and from the whole of DRC.  The article supplement provides details on the fitting.  235 
 236 
For all sites, the best fitting value for the force of rubella virus infection was used to estimate the CRS incidence 237 
per 100,000 live births among women in 5 year age groups between 15-44 years using the following expression, 238 
where s(A) is the proportion of women in age group A that are susceptible.   239 
000,100)1(65.0)(
52/16   oλeAs  240 
As in previous analyses, the risk of a child being born with CRS was assumed to be 65% if the mother was 241 
infected during the first 16 weeks of pregnancy and zero thereafter [23, 24].  The weighted CRS incidence per 242 
100,000 live births among women aged 15-44 years for each site was calculated as the average of the CRS 243 
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incidence per 100,000 live births in each 5 year maternal age group, weighted by the site-specific number of live 244 
births in each maternal age group in 2013.  The number of CRS cases born in each site was calculated by 245 
multiplying the site-specific number of live births occurring in each 5 year maternal age group by the estimated 246 
CRS incidence for each site.  CIs (95%) for the force of rubella virus infection and CRS incidence for each site and 247 
catalytic model were obtained by bootstrapping using 1,000 bootstrap datasets generated using the approach of 248 
Shkedy et al. [27].  These bootstrap-derived estimates were then used to compile the force of rubella virus 249 
infection, weighted CRS incidence per 100,000 live births in urban and rural areas and for the whole of DRC.  250 
Additional details are provided in the article supplement (Table S2).  In sensitivity analyses and for consistency 251 
with previous analyses, we repeated the analyses, treating the equivocals as seropositive.  In addition, given the 252 
discrepancy between the population size according to UN sources and that of DRC’s EPI-MOPH projections for 253 
2013, we calculated the number of CRS cases in urban and rural areas, and overall in DRC obtained by using 254 
female population size, as calculated according to UN sources [21, 22, 24].  The site-specific number of CRS cases 255 
consistent with the population size based on UN population sources were calculated by scaling down the 256 
estimates obtained using population data from DRC’s EPI-MOPH projections for 2013 by 28%. 257 
 258 
Data Analyses 259 
Data analyses were conducted using SAS version 9.2 (SAS Institute, Cary, North Carolina), EPI-INFO version 7 260 
(CDC, Atlanta, Georgia), and EXCEL version 2010 (Microsoft Corporation, Redmond, Washington).  Figure 1 was 261 
created using ArcGIS version 10.1 (Environmental Systems Research Institute, Redlands, California).  The 262 
catalytic modeling analyses were carried out using a program written in the “C” programming language [28].  263 
The fitting used an algorithm based on the simplex method of Nelder and Mead [29]. 264 
 265 
Ethical Approval 266 
The Human Subjects Research Coordinator of the Center for Global Health, CDC-Atlanta reviewed the protocol 267 
for the work described in this report.  The work was determined to be research not involving human subjects, 268 
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because it involved using unlinked/anonymous specimens collected for another purpose, and was therefore 269 
exempt from institutional review board approval.  The protocol was reviewed and approved by DRC’s MOPH. 270 
271 
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RESULTS 272 
Sera from 1,605 HIV-negative, pregnant women, aged 15-46 years, who attended ANC in Bandundu, Kasaï 273 
Occidental, and Kinshasa provinces in DRC during 2008–2009, were analyzed for rubella-specific IgG.  Relevant 274 
demographic attributes of these women are included in Table 1.  Overall and at all sites, >80% of women had 275 
their first pregnancy before age 24 years, >=50% of women had been pregnant >=3 times, and >90% had been 276 
married at some time.  The Kinshasa and Kikwit sites had the highest proportion of women having attended 277 
secondary school or higher education.  In the rural sites (Mikalayi and Vanga), farming was the most common 278 
profession, as compared with housekeeping in the urban sites (Kikwit, Kinshasa, and Tshikapa).   279 
 280 
Among the 1,605 women overall, 84% (95% CI 82, 86) were estimated to be seropositive for rubella IgG (Figure 281 
2).  Within the Kinshasa site, estimated rubella antibody seroprevalence was higher in the 20-24 year age group 282 
(89%) than the 15-19 (78%, p value =0.01) and 25-29 (75%, p value <0.001) year age groups.  In contrast, no 283 
statistically significant trends or differences in estimated rubella antibody seroprevalence among age groups 284 
were found in the overall assessment population or within the Kikwit, Vanga, Mikalayi, or Tshikapa sites (Figure 285 
2).  The association between age and antibody seroprevalence, adjusting for study site, was not significant (CMH 286 
Chi-square p value =0.10).   287 
 288 
The association between site and antibody seroprevalence, controlling for age, was statistically significant (CMH 289 
Chi-square p value =0.01).  In pairwise comparisons, Kikwit (89%) and Vanga (88%) study sites (both in Bandundu 290 
province) each had higher estimated overall rubella antibody seroprevalence than the Mikalayi (80%) and 291 
Kinshasa (82%) sites (all p values <=0.03).   292 
 293 
In the overall assessment population, estimated rubella antibody seroprevalence was similar for women 294 
declaring residence in urban (84%) versus rural (83%) settings (p value =0.67).  Moreover, no statistically 295 
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significant associations between estimated rubella antibody seroprevalence and the demographic variable 296 
categories described in Table 1 were observed.   297 
 298 
Table 2 summarizes estimates from the selected models for the force of rubella virus infection per 1,000 299 
susceptible individuals per year aged <15 and >=15 years, CRS incidence per 100,000 live births for women aged 300 
15-44 years in 2013, and the number of CRS cases born in 2013; all estimates are shown by study site, by rural 301 
and urban settings, and for DRC overall.  The estimates based upon UN population and DRC EPI-MOPH 302 
projections total population estimates are presented separately.  The best-fitting estimates of the annual force 303 
of rubella virus infection, the serological assay sensitivity, and the CRS incidence estimated from each of the 4 304 
catalytic models are described in the article supplement.  For Kikwit, Vanga, Mikalayi, and Tshikapa, the best-305 
fitting model (Model B) assumed that the force of rubella virus infection was different for persons aged <15 306 
years and those aged >=15 years and was estimated, and the sensitivity of the assay was fixed at 100% 307 
(Supplement Tables S1 and S2).  The best-fitting model for Kinshasa fit the data poorly (Supplement Figure S1 308 
and Table S2); thus Kinshasa’s antibody seroprevalence data were excluded when generating estimates for 309 
urban areas and the whole of DRC.   310 
 311 
With the exception of the Kinshasa site, where the selected best-fit model assumed that the force of rubella 312 
virus infection was identical for all age groups, the estimated force of rubella virus infection was higher for <15 313 
year olds compared to ≥15 year olds for each site, setting, and the whole of DRC, e.g. 120 per 1000 per year 314 
(95% CI 83, 159) vs 24 (95% CI 0, 73), respectively, for urban areas (Table 2).  Moreover except for Kinshasa, the 315 
forces of rubella virus infection for a given age group did not differ significantly between sites or for rural and 316 
urban settings and overall for DRC (Table 2).   317 
 318 
The estimated CRS incidence (CRS cases/100,000 live births) for 2013 ranged from 61 in both Kikwit (95% CI 0, 319 
151) and Tshikapa (95% CI 0, 202), to 92 (95% CI 0, 246) in Mikalayi.  In urban settings, the estimated CRS 320 
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incidence was 61 (95% CI 0, 186) per 100,000 live births, and the estimated number of CRS cases was 724 (95% 321 
CI 0, 2211).  In rural settings, the estimated CRS incidence was 82 (95% CI 0, 218) per 100,000 live births, and the 322 
estimated number of CRS cases was 2037 (95% CI 0, 5397).  The overall estimated CRS incidence for DRC for 323 
2013 was 69 (95% CI 0, 186) per 100,000 live births, and the estimated number of CRS cases was 2886 (95% CI 324 
342, 6395).  When the population size was based on UN population sources, the estimated number of CRS cases 325 
in 2013 in urban areas, rural areas, and overall DRC decreased to 565 (95% CI 0, 1725), 1590 (95% CI 0, 4212) 326 
and 2253 (95% CI 267,4991) respectively.  In general, including equivocal as seropositive did not greatly affect 327 
the estimates, with the confidence intervals overlapping with those obtained by treating equivocals as 328 
seronegative (Table S3 in the supplement). 329 
  330 
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DISCUSSION 331 
This is the first documentation of rubella antibody seroprevalence among WCBA in geographic areas outside of 332 
DRC’s capital, Kinshasa [11].  Availability of sera previously obtained from pregnant women attending ANC in 333 
three provinces made the study feasible [13-15].  The results indicate an overall estimated rubella antibody 334 
seroprevalence of 84% in the assessment population with a range of 80%-89% among the 5 study sites.  Rubella 335 
virus transmission is endemic in DRC, and the results in this report suggest that the majority of women are 336 
exposed to rubella virus and subsequently seroconvert before age 15 years.  No trends or differences in the 337 
estimated rubella antibody seroprevalence were observed between the age groups in the overall assessment 338 
population.   339 
 340 
A previous serosurvey in Kinshasa, conducted in 1987 among 106 women aged 16-45 years having just given 341 
birth reported high, age-independent rubella antibody seroprevalence (93%), suggesting a high level of viral 342 
transmission [11].  Other publications confirm more recent rubella virus transmission in DRC and report the 343 
majority of cases being aged <15 years with some cases among WCBA [1, 12].  Our finding of lower antibody 344 
seroprevalence in Kinshasa and lower overall antibody seroprevalence than previously documented may be 345 
explained by conducting the studies at different points in the epidemic cycle of rubella, differences in laboratory 346 
methodologies (e.g., haemagglutination inhibition versus ELISA), or differences in the age distribution of the 347 
populations [11, 30]. 348 
 349 
Our observations are generally consistent with trends in overall rubella IgG seroprevalence described among 350 
pregnant women from other countries in the WHO African region before the introduction of RCV [1, 31-52].  Our 351 
finding of no statistically significant increases in rubella antibody seroprevalence with increasing age (after 352 
approximately 15 years of age) has been observed in a number of the above-mentioned serosurveys and others 353 
[34, 35, 39, 42-46, 48, 49, 53, 54].  Moreover, in agreement with published observations from other African 354 
countries, for the assessment population in DRC overall, rubella antibody seroprevalence was similar among 355 
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women declaring residence in urban versus rural settings; however, differences in antibody seroprevalence were 356 
observed between different geographic areas in the country [31, 34, 38, 41, 43, 44, 46, 51].  Last and consistent 357 
with reports from other African countries, age at first pregnancy, number of pregnancies, civil status, 358 
educational level, and occupation were not associated with rubella antibody seroprevalence in DRC [34, 38, 41, 359 
44-46, 53].   360 
 361 
The estimate for CRS incidence of 69 per 100,000 live births for 2013 in DRC overall is consistent with estimates 362 
for other African countries and the African region as a whole; more specifically, estimates of CRS incidence in 363 
2010 for 13 African countries ranged from 19 to 283 per 100,000 live births [24].  Additionally, for the African 364 
region overall in 2010, CRS incidence was estimated to be 116 per 100,000 live births (95% CI 56, 235) [24].  DRC 365 
was among 7 African countries estimated to have >1,000 CRS cases born in 2010 [24]. 366 
 367 
To date, 8 of 47 countries in the WHO African region (Burkina Faso, Cape Verde, Ghana, Mauritius, Rwanda, 368 
Senegal, Seychelles, and Tanzania) have introduced RCV into routine vaccination schedules, given at age 9 369 
months simultaneously with measles containing vaccine [2].  In most of these countries, introduction of RCV was 370 
accompanied by a wide age range campaign targeting all children aged 9 months to 14 years (catch-up 371 
campaigns) [2, 8].  Moreover, vaccination of girls not eligible for catch-up campaigns and of WCBA is 372 
recommended through routine immunization service delivery [2].   373 
 374 
RCV introduction is planned in DRC before 2020 [10].  It is recommended that countries introducing rubella 375 
vaccination be able to maintain rubella vaccination coverage of at least 80% with at least one dose nationally 376 
either through routine immunization services or through campaigns [2, 3, 8].  A proxy indicator for being able to 377 
achieve this recommendation is a country’s experience and success with the delivery of routine measles 378 
vaccination.  Available reports indicate that DRC has had challenges with achieving national and sub-national 379 
annual measles vaccination coverage of >=80% [17, 55-57].  Therefore, during the years before introducing RCV, 380 
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DRC will need to a) focus efforts on improving the delivery of measles vaccination, thereby creating a successful 381 
platform on which to introduce rubella vaccination; b) establish an integrated nationwide measles-rubella 382 
surveillance system as well as, at least, sentinel sites for CRS surveillance; and c) use best practices from measles 383 
vaccination campaigns to assure a high-quality rubella wide-age campaign.  Moreover, as found in two Nigerian 384 
studies, awareness of rubella virus infection in DRC is probably low; therefore, increased public awareness of 385 
CRS should accompany RCV introduction [44, 46].  According to this report, a significant proportion of WCBA in 386 
DRC (including adolescent girls in whom pregnancies at age 12 years are recorded in DRC’s ANC site data) are 387 
susceptible to rubella virus infection and must be considered in the country’s RCV introduction.  Studies 388 
measuring rubella-specific IgM in pregnant women and measles case-based surveillance data from the WHO 389 
African region provide evidence that new rubella virus infections occur in adult women in Africa [1, 12, 33, 42, 390 
46, 50, 51, 54, 58]. 391 
 392 
We note that the selected catalytic model used to estimate the force of infection was a poor fit to the Kinshasa 393 
rubella antibody seroprevalence data.  This poor fit resulted from the fact that rubella antibody seroprevalence 394 
for older women remained similar to that for the youngest women, whereas catalytic models assume that the 395 
proportion of women that are susceptible decreases with increasing age, if the force of infection is non-zero and 396 
that the average force of infection is constant over time.  The similar rubella antibody seroprevalence for 397 
younger and older women in Kinshasa could have resulted from several factors which remain unclear.  For 398 
example, it could have occurred if there was much migration of either younger or older women from high or low 399 
transmission settings, respectively, into Kinshasa; if the force of infection increased disproportionately for 400 
younger people, or if, the women attending ANC were not representative of others in their age group.   401 
 402 
The analysis had limitations.  Because the ANC sites selected for the HIV sentinel serosurveys were a 403 
convenience sample of all ANC sites in the various provinces in DRC, the population of pregnant women was not 404 
designed to be representative of all pregnant women/WCBA in the health zones, provinces, or in DRC as a whole 405 
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[13, 14, 16].  Data regarding the lifetime residential history of the women in the assessment population were 406 
unavailable; thus, it was not possible to hypothesize on why higher rubella antibody seroprevalence was 407 
observed in the Kikwit and Vanga sites versus the Kinshasa and Mikalayi sites or among the 20-24 age group at 408 
the Kinshasa site.  Because the catalytic model used to estimate the force of rubella virus infection poorly fitted 409 
the Kinshasa rubella antibody seroprevalence data, the Kinshasa data were excluded when calculating the 410 
estimates for CRS incidence in urban areas, and then it was assumed that the estimated CRS incidence could be 411 
applied to Kinshasa.  The latter assumption would have led to an overestimate in the overall CRS incidence in 412 
DRC if the true force of infection in Kinshasa was so high that most women had been infected in childhood.  We 413 
acknowledge the wide confidence intervals associated with the CRS incidence and CRS case estimates and that 414 
many of the lower confidence intervals for the site and urban/rural estimates approach zero; nonetheless, the 415 
estimates provide information for DRC, beyond what is currently available in the absence of specific rubella or 416 
CRS surveillance.  However, it should be noted that the lower 95% confidence limits do not approach zero for 417 
the national estimates of the burden of CRS.   418 
 419 
CONCLUSIONS 420 
As the WHO African Region begins discussions about rubella and CRS elimination, data is needed to document 421 
the burden of rubella virus transmission/infection and of CRS prior to introducing RCV [8, 9].  In the absence of 422 
formal surveillance for rubella/CRS, the historical and current burden of both in DRC are largely unknown; 423 
however, there is evidence for rubella virus transmission [this report, 1, 11, 12].  The use of sera from HIV 424 
sentinel surveys among pregnant women attending ANC provided a unique opportunity to estimate the burden 425 
of rubella virus infection and CRS.  The results reported here can add to other available data to guide plans for 426 
introduction of RCV in DRC and will provide a background from which the impact of vaccination can be assessed.  427 
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FIGURES, FIGURE LEGENDS, AND TABLES 
Figure 1 Legend:  Approximate location of antenatal care (ANC) sites where blood specimens were collected in 
2008-2009 from pregnant women in the rubella antibody seroprevalence assessment population, by zone de 
santé (health zone) and province, Democratic Republic of the Congo.   
 
Figure 2 Legend:  Estimated seroprevalence (%) of rubella IgG in the assessment population, by age group and 
study site in Bandundu, Kasaï Occidental, and Kinshasa provinces, Democratic Republic of the Congo.   
Figure 2 Footnote:  For each age group and overall, the number of serum samples analyzed by ELISA is noted.  
Within the Kinshasa site, the 20-24 year age group had a higher antibody seroprevalence than the 15-19 (p value 
=0.01) and 25-29 (p value <0.001) year age groups.  Kikwit (89%) and Vanga (88%) study sites had higher overall 
rubella antibody seroprevalence than the Mikalayi (80%) and Kinshasa (82%) sites (all p values <=0.03).  
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Table 1:  Demographic characteristics of the rubella antibody seroprevalence assessment population, overall and by 5 study sites in Bandundu, Kasaï Occidental, and Kinshasa 
Provinces, Democratic Republic of the Congo. 
Characteristic 
Overall (n=1,605) 
No. (% of n ) 
Kikwit (n=314, urban) 
No. (% of n ) 
Vanga (n=326, rural) 
No. (% of n ) 
Kinshasa (n=323, urban) 
No. (% of n ) 
Tshikapa (n=320, urban) 
No. (% of n ) 
Mikalayi (n=322, rural) 
No. (% of n ) 
Residence 
Town  
Village 
Unknown 
 
914 (57.0) 
690 (43.0) 
1 (0.1) 
 
275 (87.6) 
39 (12.4) 
 
3 (0.9) 
323 (99.1) 
 
322 (99.7) 
0 (0) 
1 (0.003) 
 
309 (96.6) 
11 (3.4) 
 
5 (1.6) 
317 (98.5) 
Age at time of serum 
collection (years) 
15-19  
20-24  
25-29  
30-34  
>=35  
Range: 15-46 years 
 
321 (20.0) 
322 (20.1) 
318 (19.8) 
320 (19.9) 
324 (20.2) 
Range: 15-46 years 
 
64 (20.4) 
65 (20.7) 
60 (19.1) 
63 (20.1) 
62 (19.8) 
Range: 15-44 years 
 
65 (19.9) 
65 (19.9) 
66 (20.3) 
65 (19.9) 
65 (19.9) 
Range: 15-46 years 
 
64 (19.8) 
64 (19.8) 
63 (19.5) 
66 (20.4) 
66 (20.4) 
Range: 15-46 years 
 
62 (19.4) 
64 (20.0) 
66 (20.6) 
62 (19.4) 
66 (20.6) 
Range: 15-46 years 
 
66 (20.5) 
64 (19.9) 
63 (19.6) 
64 (19.9) 
65 (20.2) 
Age at first pregnancy (years) 
12-17  
18-23  
>=24  
Range: 12-37 years 
664 (41.4) 
769 (47.9) 
172 (10.7) 
Range: 12-33 years 
80 (25.5) 
176 (56.1) 
58 (18.5) 
Range: 12-33 years 
117 (35.9) 
178 (54.6) 
31 (9.5) 
Range: 13-36 years 
78 (24.2) 
186 (57.6) 
59 (18.3) 
Range: 13-37 years 
178 (55.6) 
120 (37.5) 
22 (6.9) 
Range: 13-28 years 
211 (65.5) 
109 (33.9) 
2 (0.6) 
Number of times pregnant 
including current 
1 time 
2 times 
>=3 times 
Range: 1-15  
 
367 (22.9) 
254 (15.8) 
984 (61.3) 
Range: 1-10  
 
95 (30.3) 
56 (17.8) 
163 (51.9) 
Range: 1-15  
 
70 (21.5) 
57 (17.5) 
199 (61.0) 
Range: 1-12  
 
94 (29.1) 
69 (21.4) 
160 (49.5) 
Range: 1-14  
 
55 (17.2) 
34 (10.6) 
231 (72.2) 
Range: 1-12  
 
53 (16.5) 
38 (11.8) 
231 (71.7) 
Civil Status 
Married* 
Not-married 
 
1528 (95.2) 
77 (4.8) 
 
289 (92.0) 
25 (8.0) 
 
309 (94.8) 
17 (5.2) 
 
302 (93.5) 
21 (6.5) 
 
311 (97.2) 
9 (2.8) 
 
317 (98.5) 
5 (1.6) 
Educational level 
None/1
o
 completed
+
 
>=2
o 
attended  
 
627 (39.1) 
978 (60.9) 
 
40 (12.7) 
274 (87.3) 
 
191 (58.6) 
135 (41.4) 
 
31 (9.6) 
292 (90.4) 
 
123 (38.4) 
197 (61.6) 
 
242 (75.2) 
80 (24.8) 
Occupation 
Housekeeper 
Farmer 
Other
ǂ, §
 
 
638 (40.0) 
558 (35.0) 
400 (25.0) 
 
150 (47.8) 
43 (13.7) 
119 (38.1) 
 
38 (11.7) 
244 (74.8) 
44 (13.5) 
 
168 (53.0) 
0 (0) 
149 (47.0) 
 
247 (77.4) 
14 (4.4) 
58 (18.2) 
 
35 (10.9) 
257 (79.8) 
30 (9.3) 
*Married (refers to those married monogamous, married polygamous, in a free-union, separated, divorced, and widowed), Not-married (refers to those single) 
+
None/1
o
 completed (no education, primary school attended, or primary school completed), 2
o
 (secondary school attended, secondary school completed, graduate, or license   
obtained) 
ǂ
Other (refers to student, no occupation, government worker, business person, and other).   
§
Nine responses were excluded from the analysis as their meaning could not be interpreted; the 9 were distributed as follows:  2 in Kikwit, 6 in Kinshasa, and 1 in Tshikapa.  
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Table 2.  Estimated force of rubella virus infection among susceptible individuals <15 and >=15 years of age/year, CRS incidence/100,000 live births among women 
aged 15-44 years in 2013, and estimated number of CRS cases born in 2013 by 5 study sites in Bandundu, Kasaï Occidental, and Kinshasa provinces, rural and urban 
settings, and overall in the Democratic Republic of the Congo.  Equivocals were classified as seronegative in these analyses. 
 
 
   *Confidence intervals were obtained by bootstrapping.   
  +Weighted by the number of live births occurring among women in different maternal age groups. 
  
ǂ
Compiled using estimates derived from rubella antibody seroprevalence data from Kikwit and Tshikapa.  As explained in the Methods, antibody seroprevalence data from   
Kinshasa were excluded from these estimations. 
   §Compiled using estimates derived from rubella antibody seroprevalence data from Mikalayi and Vanga. 
   
ǁ
Compiled using estimates from the urban and rural settings 
   CRS, Congenital Rubella Syndrome 
 
 
Study site or 
Setting 
Force of Rubella Virus Infection 
per 1,000 susceptible 
individuals/year 
(95% Confidence Intervals)* 
Estimated weighted  
CRS Incidence/ 
100,000 live births among 
women aged 15-44 years in 
2013+ (95% Confidence 
Intervals)* 
Estimated number of CRS cases born in 2013 
(95% Confidence Intervals)*, with the population size obtained from: 
<15 years of 
age 
>=15 years of 
age 
Democratic Republic of the Congo Expanded 
Programme on Immunization-Ministry of 
Public Health Population projections based 
on the 1984 census 
UN population sources [21] 
Kikwit 129 (98, 164) 27 (0, 69) 61 (0, 151) 5 (0, 11) 3 (0, 8) 
Vanga 118 (88, 155) 32 (0, 72) 81 (0, 184) 11 (0, 24) 8 (0, 18) 
Mikalayi 92 (64, 120) 23 (0, 68) 92 (0, 246) 10 (0, 26) 7 (0, 18) 
Tshikapa 113 (80, 146) 20 (0, 73) 61 (0, 202) 8 (0, 26) 6 (0, 18) 
Kinshasa 66 (59, 72) 66 (59, 72) 252 (238, 264) 73 (68, 76) 52 (49, 55) 
Urbanǂ 120 (83, 159) 24 (0, 73) 61 (0, 186) 724 (0, 2211) 565 (0, 1725) 
Rural§ 104 (70, 149) 28 (0, 71) 82 (0, 218) 2037 (0, 5397) 1590 (0, 4212) 
Overallǁ 110 (71, 152) 27 (0, 72) 69 (0, 186) 2886 (342, 6395) 2253 (267, 4991) 
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